Development of a Curative Treatment within the AML-BFM Studies

The first multicenter treatment study for AML in childhood in Germany was performed from 1978 onwards. The therapy plan was designed similar to that for the acute lymphoblastic leukaemia (ALL). The drugs with the highest efficacy in AML, cytarabine cutting catara-bine and anthracyclines, were combined during induction and consolidation, followed by preventive cranial irradiation and maintenance therapy similar to that in ALL. The remission rate of the initial study was 80%, and the 5-year survival rate increased from less than 10% before 1970 to 40%. 5 subsequent trials have further increased the 5-year survival to now 70% and even 90% in the subgroup of core-binding factor leukaemias by using an intensified and optimised treatment schedule.The AML-BFM studies were the only prospective study sequence testing the benefit of cranial irradiation. Results from study -87 including the non-randomized patients showed an increased risk of CNS and/or bone marrow relapses in non-irradiated patients. Later on there was evidence that 12 Gy resulted in the same relapse rate as 18 Gy. The AML-BFM studies always used the experience from the previous study to optimize the next study. This approach was essential together with improved supportive treatment and experience of the medical staff for the step-wise and considerable increase of longterm survival within the 6 subsequent AML-BFM studies.

[1]  D. Reinhardt,et al.  Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study , 2010, British journal of haematology.

[2]  D. Reinhardt,et al.  Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. , 2008, Blood.

[3]  D. Reinhardt,et al.  current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation? – A European view , 2002, British journal of haematology.

[4]  D. Reinhardt,et al.  AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity , 2005, Leukemia.

[5]  J. Ritter,et al.  Early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia. Associations with hyperleukocytosis and acute monocytic leukemia , 1987, Cancer.

[6]  G. Henze,et al.  [Quality management within the competence network of paediatric oncology and haematology]. , 2003, Klinische Padiatrie.

[7]  D. Reinhardt,et al.  Treatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early deaths in children , 2001, Annals of Hematology.

[8]  H. Gralnick,et al.  Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML‐MO) , 1991, British journal of haematology.

[9]  D. Reinhardt,et al.  Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  U. Creutzig,et al.  A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. , 2010, Blood.

[11]  D. Reinhardt,et al.  Study AML-BFM 2004: Improved Survival In Childhood Acute Myeloid Leukemia without Increased Toxicity , 2010 .

[12]  A. Teigler‐Schlegel,et al.  Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16). , 2011, Blood.

[13]  C. Niemeyer,et al.  Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93 , 2001, Leukemia.

[14]  J. Ritter,et al.  Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukemia? Unexpected results of the Childhood Acute Myelogenous Leukemia Study BFM-87. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  S. Feig,et al.  Guidelines for pediatric cancer centers. , 2004, Pediatrics.

[16]  K. Jahnukainen,et al.  Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  F. Berthold,et al.  Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Hanada,et al.  Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  H. Kantarjian,et al.  Clinical Activity of Farnesyl Transferase Inhibitors in Hematologic Malignancies: Possible Mechanisms of Action , 2004, Leukemia & lymphoma.

[20]  Zhen-yi Wang,et al.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. , 1988, Haematology and blood transfusion.

[21]  G Flandrin,et al.  World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Harbott,et al.  Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. , 1995, Blood.

[23]  K. Wheatley,et al.  Results of a randomized trial in children with Acute Myeloid Leukaemia: Medical Research Council AML12 trial , 2011, British journal of haematology.

[24]  D. Reinhardt,et al.  [Genetic prognostic factors in childhood acute myeloid leukemia]. , 2012, Klinische Padiatrie.

[25]  R. Hills,et al.  Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  G. Gustafsson,et al.  Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO‐AML trials , 2003, British journal of haematology.

[27]  S. Shurtleff,et al.  Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. L. Beau,et al.  Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome , 2002, Nature Genetics.

[29]  Elaine Coustan-Smith,et al.  Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. , 2010, The Lancet. Oncology.

[30]  D. Reinhardt,et al.  Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Ritter,et al.  The childhood AML studies BFM-78 and -83: treatment results and risk factor analysis. , 1987, Haematology and blood transfusion.

[32]  D. Reinhardt,et al.  Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials , 2010, Leukemia.

[33]  C. Pui,et al.  Current management and challenges of malignant disease in the CNS in paediatric leukaemia. , 2008, The Lancet. Oncology.

[34]  G. Henze,et al.  Definition of a standard‐risk group in children with AML , 1999, British journal of haematology.

[35]  S. Bielack,et al.  Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties? , 1996, European journal of cancer.

[36]  D. Reinhardt,et al.  The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study , 2012, Haematologica.

[37]  H. Hasle.  Pattern of malignant disorders in individuals with Down's syndrome. , 2001, The Lancet. Oncology.

[38]  D. Reinhardt,et al.  Gemtuzumab Ozogamicin (Mylotarg®) in Children with Refractory or Relapsed Acute Myeloid Leukemia , 2004, Oncology Research and Treatment.

[39]  J. Merker,et al.  Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. , 2008, Blood.

[40]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[41]  F. Locatelli,et al.  Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols , 2005, Leukemia.

[42]  R. Gray,et al.  Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. , 1998, British journal of haematology.

[43]  G. Henze,et al.  Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials , 2005, Leukemia.

[44]  D. Reinhardt,et al.  Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  R. Foà,et al.  GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. , 2005, Blood.

[46]  W. Tissing,et al.  Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. , 2003, Blood.

[47]  G. Henze,et al.  Improved treatment results in childhood acute myelogenous leukemia: a report of the German cooperative study AML-BFM-78. , 1985, Blood.

[48]  D. Reinhardt,et al.  CNS irradiation in pediatric acute myleoid leukemia: Equal results by 12 or 18 Gy in studies AML‐BFM98 and 2004 , 2011, Pediatric blood & cancer.

[49]  J. Buckley,et al.  A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. , 2001, Blood.

[50]  G. Henze,et al.  Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses , 2010, British journal of haematology.

[51]  V. Cornelius,et al.  Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials , 2010, BMC Cancer.

[52]  S. Scherer,et al.  GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. , 2003, Blood.

[53]  A Orfao,et al.  Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). , 1995, Leukemia.